


Attorney Docket No.: 6263.200



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anker Steen Jorgensen

Serial No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 3030

For: Glucagon Antagonists/Inverse Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (29 Total)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on January 10, 2002.

Sylvia Gonzalez
(name of person mailing paper)

(signature of person mailing paper)

BEST AVAILABLE COPY

Attorney Docket No.: 6263.200-US



TECH CENTER 1600/2900

PATENT

JAN 29 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anker Steen Jorgensen

Application No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 3030

For: Glucagon Antagonists/Inverse Agonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 00/39088
2. WO 94/14426
3. WO 98/04528

BEST AVAILABLE COPY

4. WO 98/21957
5. WO 98/22108
6. WO 98/22109
7. WO 99/01423
8. WO 97/16422
9. WO 98/24780
10. WO 98/24782
11. WO 99/24404
12. WO 99/32448
13. US 5,880,139
14. US 5,776,954
15. US 4,359,474
16. US 4,374,130
17. US 5,837,719
18. C.L. Brand et al., "Immunoneutralization of endogenous glucagons with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats" *Diabetologia* Vol. 37 pgs. 985-993 (1994)
19. C.L. Brand et al., [535] *Diabetes* 43, [suppl 1], 172A (1994)
20. C. L. Brand et al., *Am. J. Physiol.* 269, E469-E477 (1995)
21. C.L. Brand et al., [492] *Diabetes* 44 [suppl 1], 134A (1995)
22. C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits", *Diabetes* Vol. 45., pages. 1076-1083 (1996)
23. L.J.Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" *Science* Vol. 259., pages. 1614-1616 (1993)
24. C.G. Unson et al., "Biological Activities of des-His¹ [Glu⁹]Glucagon Amide, a Glucagon Antagonist¹" *Peptides*, Vol.10 pages 1171-1177 (1998)
25. Post et al., "Mechanism of action of des-His¹-[Glu⁹]glucagons amide, a peptide antagonist of the glucagons receptor sytem" *Proc. Natl. Acad. Sci* Vol. 90 pages 1662-1666 (1993)
26. Azizeh et al., "[des His¹, des Phe⁶, Glu⁹]GLUCAGON AMIDE: A NEWLY DESIGNED "PURE" GLUCAGON ANTAGONIST", *Bioorganic & Med Chem Ltr*, Vol. 5. No. 16, pages. 1849-1852 (1995)
27. Unson et al., "Multiple-site Replacement Analogs of Glucagon" *The Journal of Biological Chemistry* Vol. 17, Issue of April 29, pages. 12548-12551 (1994)
28. J.L. Collins et al., "CP-99, 711: A NON-PEPTIDE GLUCAGON RECEPTOR ANTAGONIST" *Bioorganic & Med. Chem. Ltr.* Vol. 2, No. 9 pages. 915-918 (1992)
29. P. Madsen et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists" *J. Med. Chem* Vol. 41, pages. 5150-5157 (1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: January 10, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Anker Steen Jorgensen**Filing Date **November 16, 2001**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,880,139	03/09/99	L.L. Chang	514	326	11/17/97
	5,776,954	07/07/98	de Laszlo et al	514	340	10/30/96
	4,359,474	11/16/82	Anderson et al	424	273	11/28/80
	4,374,130	02/15/83	Barcza	424	184	02/15/83
	5,837,719	11/17/98	de Laszlo et al	514	343	08/08/96

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/39088	06/07/00	WIPO				
	WO 94/14426	07/07/94	WIPO				
	WO 98/04528	05/02/98	WIPO				
	WO 98/21957	28/05/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C.L. Brand et al., 'Immunoneutralization of endogenous glucagons with Monoclonal glucagons antibody normalizes hyperglycaemia in moderately Streptozotocin-diabetic rats' 'Diabetologia, Vol. 37 pgs.985-993 (1994)
	C.L. Brand et al., [535] Diabetes 43, [suppl 1], 172A (1994)
	C.L. Brand et al., Am J. Physiol. 269, E469-E477 (1995)
	C.L. Brand et al., [492] Diabetes 44 [suppl 1], 134A (1995)
	C.L. Brand et al., 'Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan Induced Diabetic Rabbits', Diabetes Vol. 45, pgs. 1076-1083 (1996)
	L.J. Jelinek et al., 'Expression Cloning and Signaling Properties of the Rat Glucagon Receptor' 'Science Vol. 259, pgs. 1614-1616 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

(Rev. 6-92)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6263.200-US

Serial No. 09/995,988

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Anker Steen Jorgensen

(Use several sheets if necessary)

Filing Date November 16, 2001

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/22108	28/05/98	WIPO				
	WO 98/22109	28/05/98	WIPO				
	WO 99/01423	14/01/99	WIPO				
	WO 97/16442	09/05/97	WIPO				
	WO 98/24780	11/06/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		C.G. Unson et al., ''Biological Activities of des-His ¹ [Glu ⁹]Glucagon Amide, A Glucagon Antagonist'' Peptides, Vol. 10 pgs 1171-1177(1998)
		Post et al., ''Mechanism of action of des-His ¹ [Glu ⁹]Glucagon Amide: A Peptide antagonist of the glucagons receptor system'' Proc.Natl. Acad. Sci Vol. 90., pages 1662-1666 (1993)
		Unson et al., ''Multiple-site Replacement Analogs of Glucagon'' The Journal of Biological Chemistry Vol. 17, Issue of April 29, pgs. 12548-12551 (1994)
		J.L. Collins et al., ''CP-99, 711: A Non-Peptide Glucagon Receptor Antagonist'' Bioorganic & Med.Chem. Ltr. Vol.2, No.9, pgs.915-918(1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

FORM PTO-1449
(Rev. 2-22)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **6263.200-US**Serial No. **09/995,987**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Anker Steen Jorgensen**Filing Date **November 16, 2001**Group **To be assigned**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/24782	11/06/98	WIPO				
	WO 99/24404	20/05/99	WIPO				
	WO 99/32448	01/07/99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Azizeh et al., "[des His ¹ , des Phe ⁶ , Glu ⁹]Glucagon Amide: A Designed "Pure" Glucagon Antagonist", Bioorganic & Vol. 5, No. 16 pages. 1849-1852 (1995)
		P. Madsen et al., "Discovery and Structure-Activity The First Non-Peptide Competitive Human Glucagon Receptor J. Med.Chem. Vol. 41, pages 5150-5157 (1998)®

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY